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Abstract 
Background: The increasing use of gold nanoparticles (AuNPs) in the field of neuroscience instilled hope for their 
rapid translation to the clinical practice. AuNPs can be engineered to carry therapeutics or diagnostics in the diseased 
brain, possibly providing greater cell specificity and low toxicity. Although there is a general enthusiasm for these 
tools, we are in early stages of their development. Overall, their brain penetrance, stability and cell specificity are criti-
cal issues that must be addressed to drive AuNPs to the clinic.
Results: We studied the kinetic, distribution and stability of PEG-coated AuNPs in mice receiving a single injection 
into the cisterna magna of the 4th ventricle. AuNPs were conjugated with the fluorescent tag Cy5.5 (Cy5.5-AuNPs) 
to track their in vivo distribution. Fluorescence levels from such particles were detected in mice for weeks. In situ 
analysis of brains by immunofluorescence and electron microscopy revealed that Cy5.5-AuNPs penetrated the brain 
parenchyma, spreading in the CNS parenchyma beneath the 4th ventricle. Cy5.5-AuNPs were preferentially found in 
neurons, although a subset of resting microglia also entrapped these particles.
Conclusions: Our results suggest that the ICM route for delivering gold particles allows the targeting of neurons. This 
approach might be pursued to carry therapeutics or diagnostics inside a diseased brain with a surgical procedure that 
is largely used in gene therapy approaches. Furthermore, this approach could be used for radiotherapy, enhancing 
the agent’s efficacy to kill brain cancer cells.
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Background
A wide interest in the field of nanomedicine involves 
structurally different nanovectors, and in particular func-
tionalized nanoparticles. Given their excellent biocom-
patibility and stability, nanoparticles are used to deliver 
drugs, genes, fluorescent labels, imaging agents, and 
enhancing radiotherapy tools. More recently, they were 
proposed as antiviral agents [1, 2]. Accordingly, more 
than 200 nano-objects targeted toward nanomedicine are 
currently approved for clinical trials in patients, while a 
larger number is engaged in pre-clinical studies [3].
Despite encouraging results indicate that nanovec-
tors are reliable tools to treat a considerable number of 
pathologies, their use in disorders of central nervous 
system (CNS) is hampered by some limitations. A major 
challenge for their usage in CNS is their limited ability to 
cross the blood brain barrier (BBB), which often prevents 
to attain effective pharmacokinetic levels of therapeu-
tics in the brain. Recent advances led to the generation 
of improved nanoparticles showing increased CNS pen-
etration [4], therefore opening new avenues in basic and 
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clinical neuroscience [5]. Among such particles, metallic 
nanoparticles are extremely attractive tools for their bio-
physical characteristics [6]. Gold nanoparticles (AuNPs) 
display unique optical and electronic properties to be 
considered reliable tools for drug/gene delivery, biomedi-
cal imaging [7], photothermal and microwave therapies 
[8]. AuNPs can be easily and uniformly functionalized 
with different chemical groups, allowing these particles 
to target specific locations in different organs as well as 
to reduce toxicity [9, 10]. AuNPs display size-dependent 
kinetics and distribution when injected in tissues [11, 
12]. The intravenous injection of AuNPs results in accu-
mulation of particles in several organs, including the 
brain. Interestingly, particles with sizes in the range of 
15–50 nm cross the BBB better than particles with big-
ger diameters [12, 13]. The surface functionalization has 
a great impact on pharmacokinetic properties of AuNPs 
[4]. For example, transferrin-coated nanoparticles enter 
the brain through transcytosis and are more BBB-pene-
trant than other types of functionalized AuNPs [14]. Pol-
yethylene glycol (PEG) coating of AuNPs increases their 
solubility and reduces toxicity [15]. Indeed, in a model of 
spinal cord contusion the local injection of PEG-coated 
AuNPs improved functional recovery and attenuated 
demyelination [16]. Insulin coated AuNPs crossed the 
BBB, reaching the brain with concentrations that are 
around 5% of the total injected dose [17]. However, 2 days 
after the delivery, the concentration of particles in the 
brain drops to values around 1–2% of the injected dose 
[13]. Imaging studies further corroborate these observa-
tions, showing that once AuNPs get into the brain, they 
rapidly disappear [17–21]. Intra-carotid injection of 
AuNPs increases the penetrance of particles in the brain, 
although their diffusion in the parenchyma is limited to 
few microns from the visible vessels [22]. Repeated treat-
ments can increase the penetrating amount of AuNPs in 
the brain [6, 17, 23], although an uncontrolled accumu-
lation of AuNPs in neurons could create some adverse 
effects, such as alterations of the firing properties of 
neurons [24]. Therefore, we must take in consideration 
such aspect if we plan therapeutic strategies for chronic 
diseases/applications.
The use of intra-parenchymal injections or the implan-
tation of catheters, both by-passing the BBB, have the 
great limit of requiring invasive surgical procedures. 
Likely, both approaches can trigger undesired local 
inflammatory responses [25, 26]. A strategy to increase 
the penetrance and the permanence of appropriate con-
centrations of AuNPs in the CNS, that avoids the use of 
serial injections, requires alternative routes of admin-
istrations. In a model of focal lesion, such as the spinal 
cord injury, PEG-AuNPs injected in two sites that flanked 
the lesion epicenter efficiently supported the functional 
recovery of mice [16]. In spite of this noteworthy result, 
we can speculate that such procedure will find some limi-
tations in diseases featuring large or disseminated brain 
lesions, such as multiple sclerosis (MS). Among alterna-
tive approaches to delivery AuNPs, the intrathecal route 
offers several advantages and it has been used to deliv-
ery drugs, as well as to infuse the brain with anesthet-
ics, trophic factors and antibodies, although it has never 
been used to deliver nanoparticles [27, 28]. Experiments 
of gene delivery in mice clearly demonstrated that the 
intra cisterna magna (ICM) route is safe [29–31]. Indeed, 
gene therapy experiments showed that ICM injection of 
lentivirus leads viruses to diffuse consistently in all cere-
brospinal fluid (CSF) spaces, infecting both choroidal and 
ependymal cells [29].
Growing evidence from several studies suggests that 
non-invasive imaging procedures to track the bio-dis-
tribution of AuNPs at different time points are excellent 
tools to accomplish the goal of using AuNPs in a clinical 
setting. The in vivo near infrared optical imaging of flu-
orescent-coated AuNPs is a relatively novel fluorescence 
imaging (FLI) approach that overcomes some previous 
limits of in vivo imaging, offering an excellent resolution 
and, above all, a limited invasiveness [17].
In this study, we characterized mice receiving ICM 
delivery of PEG functionalized and Cy5.5 labelled AuNPs 
(Cy5.5-AuNPs). We observed robust accumulation of 
Cy5.5-AuNPs in the CNS of mice, receiving a single 
injection of particles. Injected mice did not show signs 
of distress or pain. Remarkably, in vivo imaging showed 
detectable signals for more than 20  days. Confocal and 
electron microscopy analyses revealed that Cy5.5-AuNPs 
internalization in scattered neurons along the CNS 
parenchyma with some of them located several hundred 
microns far from the ependymal layer.
Results
Synthesis and characterization of Cy5.5‑AuNPs
We recently developed a new method based on a Turk-
evich-modified ‘one-pot’ strategy to obtain large batches 
of functionalized AuNPs, that avoids the purification of 
intermediate citrate-stabilized nanoparticles [32]. PEG 
coating guarantees the indispensable colloidal stabil-
ity and water dispersibility, making AuNPs undetect-
able by macrophages [33]. Taking advantage from this 
functionalization, we conjugated PEG-AuNPS with the 
near infrared fluorescent dye Cy5.5 (excitation/emis-
sion: 674/710  nm, having an ideal spectrum for in  vivo 
imaging and limiting tissue auto-fluorescence). Purified 
Cy5.5-AuNPs were stable for months when kept at 4 °C, 
without any trace of nanoparticles aggregation or Cy5.5. 
dye degradation as detected by DLS and fluorescence 
measurements. The obtained spherical Cy5.5-AuNPs 
Page 3 of 13Spinelli et al. J Nanobiotechnol           (2019) 17:49 
showed a size distribution centered at 18.03 ± 4.9 nm as 
determined by transmission electron microscopy (TEM) 
analysis (Fig. 1A). They showed the typical UV–vis spec-
trum with the maximum plasmonic absorption band at 
523 nm (Fig. 1B). The presence of high molecular weight 
PEG coating the metal surface is confirmed by the deter-
mination of a hydrodynamic diameter value of 50.92 nm 
(Fig. 1C and Additional file 1: Figure S1) [34].
In vitro characterization of Cy5.5‑AuNPs toxicity
We assayed the cytotoxicity of Cy5.5-AuNPs on primary 
neuronal cultures established from the hippocampus 
of E17.5 murine embryos. Neurons, cultured 15  days 
in vitro, exhibited the typical arborization of mature cells. 
At this time point, they usually display spontaneous neu-
ronal activity organized in functional networks [35, 36]. 
We used FLI to establish fluorescence levels of a range 
of Cy5.5-AuNPs concentrations. We imaged plates con-
taining increasing concentrations of particles and using 
675/720 filters we established a correlation between 
fluorescence levels and AuNPs concentrations (Fig.  2a, 
b). We next incubated neurons with increasing amount 
of Cy5.5-AuNPs to measure rates of cell death. Twenty-
four hours after seeding neurons with particles, we evalu-
ated percentages of dying neurons scoring  Sytox+ cells 
(Fig. 2c). We observed a slight increase of cell death rates 
in neurons receiving the highest concentration of Cy5.5-
AuNPs, although these levels did not statistically dif-
fer from values recorded in untreated neurons (Fig. 2c). 
However, lower concentrations of Cy5.5-AuNPs did 
percentages of  Sytox+ cells that not exceed rates meas-
ured in untreated cultures (Fig.  2c). We next fixed and 
labelled cells for NeuN and GFAP, which are markers of 
neurons and astrocytes respectively. We did not observe 
unspecific Cy5.5 signals in untreated cells (Fig. 2d, right 
column). Cultures receiving Cy5.5-AuNPs showed Cy5.5 
fluorescence in regions containing clusters of  NeuN+ 
cells. While the localization of Cy5.5 signals appeared 
uncorrelated with the distribution of  GFAP+ cells, 
(Fig. 2d left column). Altogether, these results suggests a 
general low cytotoxicity of PEG-coated Au particles for 
cultured hippocampal neurons [37].
In vivo delivery of Cy5.5‑AuNPs
We next administered AuNPs to adult mice, establish-
ing their pharmacokinetic distribution in the brain. We 
initially performed a single s injection of Cy5.5-AuNPs in 
the tail vein of mice. We used an equal amount of soluble 
Cy5.5 to establish control mice. We recorded FLI 5 days 
after the delivery of Cy5.5-AuNPs. We calculated the flu-
orescence ratio (FR) in each animal (see “Methods” sec-
tions for details). However, fluorescence levels measured 
in both groups did not exceed the background levels, and 
did not allow a robust calculation of FR levels (Additional 
file 2: Figure S2A). We next examined Cy5.5 fluorescence 
in the cortical wall of these mice using the NeuN marker 
to identify neurons. However, levels of Cy5.5 measured in 
both groups were did not exceed the general background 
(Additional file 2: Figure S2B and C).
We subsequently performed an intra parenchymal 
injection of Cy5.5-AuNPs targeting the presumptive 
somatosensory cortex of mice. Due to the small vol-
ume of Cy5.5-AuNPs that we delivered in brains, the 
fluorescence levels of Cy5.5 were hardly detectable in 
living mice. However, we detected signals that were 
more robust when we scored FLI in isolated brains 
collected 5  days after the injection of particles (Addi-
tional file 3: Figure S3A). Signals were concentrated in 
Fig. 1 Characterization of AuNPs. A TEM image of AuNPs. The AuNPs have a spherical shape with a diameter (mean ± S.D.) of 18.03 ± 4.93 nm. 
B UV–vis spectrum of AuNPs. The maximum absorbance of the plasmonic peak is at 523 nm. C Hydrodynamic diameter (nm) distribution of 
Cy5.5-AuNPs, obtained by dynamic light scattering (DLS) measurements. The intensity-mediated measure gives a mean hydrodynamic diameter of 
50.92 nm
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spots localized in the presumptive somatosensory cor-
tex (Additional file 3: Figure S3A). FLI of 500 µm thick 
coronal slabs further confirmed that highest Cy5.5 sig-
nal was deriving from the somatosensory cortex (Addi-
tional file  3: Figure S3B). AuNPs with a size of 20  nm 
absorb 530 nm wavelength and emit a wavelength that 
peaks at 610  nm, which is sufficiently intense to be 
detected by a fluorescence microscope [38]. Therefore, 
we performed serial imaging of adjacent sections, scor-
ing the somatosensory cortical wall. We labelled 20 µm 
thick sections for NeuN and by confocal microscopy we 
observed the almost perfect co-localization of Cy5.5 
signals with Au signals (Additional file 4: Figure S4A, B) 
in several cortical  NeuN+ cells (Additional file 4: Figure 
S4C, D).
We next labelled parallel sections for the microglia/
macrophages Iba1 to establish whether the injection 
procedures may alter the cortical morphology. We used 
Iba1 to label reactive microglia/macrophages, both 
associated to focal CNS injuries [39].  Iba1+ cells were 
scored in regions surrounding the site of the injection 
(ipsilateral cortex) as well as in the controlateral cor-
tex, not receiving any manipulation (Additional file  3: 
Figure S3C, D). We observed a moderate to high gliosis 
featured by a significant increase of  Iba1+ cells in the 
ipsilateral cortex (Additional file 3: Figure S3E). There-
fore, we reasoned that the relative high abundance of 
 Iba1+ Cy5.5-AuNPs+ cells in the ipsilateral cortex 
could mirror the activation of phagocytosis (Additional 
file 3: Figure S3F), a classical phenomenon that occurs 
in response to tissue damage [40].
We next performed ICM delivery of either Cy5.5-
AuNPs or the unconjugated Cy5.5 [41]. Upon Cy5.5-
AuNPs injections, we performed FLI analysis of Cy5.5 at 
different time points. Intense Cy5.5 fluorescence signals 
were detected in regions encompassing the 4th ventri-
cle of mice injected with Cy5.5-AuNPs (Fig. 3a). Calcu-
lated FR levels peaked 1 day after the injection, although 
Fig. 2 Cy5.5AuNPs do not elicit cytotoxicity in primary neuronal 
cultures. a Four representative plates of a 96 wells-plate containing 
200 μl of Cy5.5-AuNPs at four different concentrations that range 
from 1 to 0.001 mg/ml. Images were acquired using the 675/720 
filters and averaged radiant efficiencies were measured using a 
circular ROI superimposed on each well. Histogram of b shows the 
linearity between the radiant efficiency and AuNPs concentration. c 
Percentages (± S.D.) of dying hippocampal neurons in cultures treated 
with AuNPs. Percentages (± S.D.) of dying cells, scored with Sytox, are 
shown on c. Inset shows a representative picture derived from cultures 
receiving AuNPs for 24 h, n = 4 independent cultures. d Au-NPs 
distribution in hippocampal cultures receiving 0.1 mg/ml of Cy5.5-NPs 
for 24 h. Cultures were labelled for GFAP to identify astrocytes (upper 
row d) and NeuN to identify neurons (lower row d). Scale bar 15 µm for 
c and 40 µM for d 
considerable high fluorescence signals were still detect-
able  25  days after the injection (Fig.  3c). On the other 
hand, scant fluorescence levels were observed in mice 
treated with the unconjugated Cy5.5 (Fig. 3b, d).
▸
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We next calculated Au concentrations in brain explants 
obtained from mice receiving ICM injection of Cy5.5-
AuNPs. The Cy5.5-injected group was not included 
in this experiment since we reasoned that FR signals 
were close to background levels as shown in the pre-
vious experiment (Fig.  3d). Two and five days upon 
Cy5.5-AuNPs delivery, mice were perfused with saline 
to remove particles potentially retained in the blood 
Fig. 3 Longitudinal distribution of AuNPs in ICM-injected mice. a FLI imaging of a single animal receiving ICM injection of Cy5.5-AuNPs. Pictures 
were recorded at different time points (1 h, 1, 2, 3, 4, 7, 10, 16 and 25 days after the injection). FLI levels recorded in a control animal receiving ICM 
injection of unconjugated Cy5.5 are shown in b. The epi-fluorescence scale used in both experiments is shown on the right side of the panel. Plots 
in c, d show quantifications of FR levels (mean ± S.D.) in mice receiving Cy5.5-AuNPs (c) as well as in mice receiving soluble Cy5.5 (d), (n = 3 for each 
group)
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circulation. We dissected each brain to obtain coro-
nal slabs that spanned from the anterior bregma − 5.5 
to the posterior bregma − 8.5. Explants were digested 
over a heating plate by adding a solution of  HNO3/H2O2 
30% m/m (3/1) followed by aqua regia, and the amount 
of Au in each of them was detected by Inductively Cou-
pled Plasma-Optical Emission Spectrometers (ICP-OES). 
Au was undetectable in vehicle-treated mice, while a 
significant amount of Au was detected in Cy5.5-AuNPs 
injected mice at both time points (Fig. 4).
Ex‑vivo localization of Cy5.5‑AuNPs in ICM injected brains
We next investigated the uptake of Cy5.5-AuNPs in fixed 
brains sections, sampling brains from mice sacrificed 
30 days after ICM delivery of Cy5.5-AuNPs. Using confo-
cal microscope, we acquired Cy5.5 and Au fluorescence 
in order to increase the signal to noise ratio, the signal 
specificity, and to provide a better estimation of Cy5.5-
AuNPs distribution [38]. We scored scattered  NeuN+ 
cells in the presumptive medial vestibular nucleus that 
were positive for Cy5.5-AuNPs (Fig.  5A, B). Conversely, 
sections labelled for GFAP (Fig. 5C, D) and for the mye-
lin marker MBP (Fig. 5E, F) showed very few, if any, cells 
containing Cy5.5-AuNPs. We next labelled sections for 
Iba1 and we observed some putative microglia display-
ing the ramified cell morphology of bona fide resting cells 
that were positive for Cy5.5-AuNPs (Fig. 5G, H). Control 
brains derived from mice injected with soluble Cy5.5 did 
not show any detectable signal for Cy5.5 and Au (Fig. 5A, 
C, E and G). We next assessed the localization of Cy5.5-
AuNPs in the CNS by TEM, sampling sections in a region 
encompassing the 4th ventricles. Cy5.5-AuNPs were 
observed in few ependymal cells (not shown), while we 
observed particles in parenchymal cells. Nanoparticles 
were detected in some electron dense vacuoles, possibly 
belonging to lysosomal compartment (Fig.  5I). We next 
calculated percentages of  NeuN+ Cy5.5+Au+ cells in the 
pons/medulla of ICM-injected mice that we sacrificed at 
day 15 (Fig.  6A, C). Control mice injected with uncon-
jugated Cy5.5 displayed signals that were undistinguish-
able from background levels (Fig.  6A, C). On the other 
hand, we observed intense Cy5.5 levels in mice receiv-
ing particles (Fig.  6B). We next went to the tissue scor-
ing Au and Cy5.5 in NeuN-expressing cells located in the 
pons/medulla, a region placed beneath the 4th ventri-
cles (boxed area of Fig. 6D). Around 23% of  NeuN+ cells 
showed Au and Cy5.5 signals in the cytoplasm (Fig. 6E, 
F). Of note, some triple positive cells were relatively far 
from the ventricular lining, suggesting that AuNPs can 
spread in the CNS parenchyma (arrows in Fig. 6D).
Discussion
A considerable number of putative drugs lacks the abil-
ity to penetrate the BBB, and for this limitation none of 
them were further pursued as therapeutics. The func-
tionalization of nanovectors with these molecules 
could, in principle, overcome such limitation, allowing 
their diffusion in diseased brains. Thus, the physiologi-
cal barrier represented by the BBB could be crossed by 
nanoparticle-supported drugs able then to interact with 
their targets. However, after an initial enthusiasm for this 
approach, it became clear that the general efficiency of 
nanovectors to cross the BBB was modest [17–21]. In this 
context, AuNPs have attracted attention for their safety 
and biophysical characteristics [42]. The direct injection 
of AuNPs in the CNS parenchyma is attractive, although 
our data indicate that such procedure may generate tissue 
damage and microglia activation. Intranasal administra-
tion of AuNPs, conversely, leads to their uptake in differ-
ent brain regions and is a promising method for the BBB 
passage of nanoparticles, although the regional distribu-
tion in the brain of molecules may vary from substance to 
substance, and additional studies are needed to validate 
this approach [43]. Repeated intravenous injections of 
nanoparticles, often using high dosages to achieve BBB 
permeation, could induce their accumulation in the liver 
causing inflammation and apoptosis and may alter neu-
ronal functions [41, 44]. A recent study, showing in vivo 
instability of coated AuNPs, adds a further layer of com-
plexity, suggesting that using AuNPs to deliver molecules 
as well as their tracking in living animals may be influ-
enced by a certain degree of molecular instability and/
or cell metabolism [45]. Indeed, fluorochrome-coated 
AuNPs are processed by lysosomes in the liver, and mol-
ecules tagging AuNPs can be cleaved by proteolysis [45]. 
These experimental observations should be considered in 
the interpretation of distribution studies after systemic 
administration of AuNPs.
For these reasons, we attempted to deliver Cy5.5-
AuNPs directly in the brain using a single intrathecal 
Fig. 4 ICP-OES analysis of brain Au contents. Adult mice received 
ICM injections of Cy5.5-AuNPs or vehicle and brains were collected 
2 and 5 days after the delivery (n = 3 for each group). Plot reports 
means (± S.D.) of the total amount of Au (mg) found in the brain 
homogenates (mg) at each time point
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Fig. 5 Distribution of Cy5.5-AuNPs in ICM-injected mice. Confocal images of sections (maximum projections) from the pons/medulla of mice 
sacrificed 30 days after ICM injections. Acquisitions were done to capture Cy5.5 and Au signals in control mice—i.e. receiving Cy5.5 (A, C, E and 
G)—and in mice receiving Cy5.5-AuNPs (B, D, F and H). A, B Triple labelling for NeuN, Cy5.5 and Au. Arrows indicate cells that are shown at high 
magnifications in insets. C, D Confocal images of adjacent sections labelled for Cy5.5, Au and GFAP. E, F Triple labelling for MBP, Cy5.5 and Au. Arrow 
in F indicates a region that is shown at high magnification in the inset. G, H Confocal images of sections labelled for Iba1, Cy5.5 and Au. The arrow 
in H indicates one  Iba1+ cells that is shown at high magnification in the inset (n = 3 for each group). I Au nanoparticles localized in vacuoles of 
parenchymal cells of brains sampled at day 15. Arrows indicate several Au particles in a putative lysosome of a cell (n = 2). Scale bar 50 µm for A–H, 
0.1 µm for I 
injection. This approach has been extensively used in the 
past to deliver lentiviral particles and drugs [30]. ICM 
injections are well characterized for such vectors, but lit-
tle is known regarding their use to deliver AuNPs. Our 
experimental evidence shows that this route of adminis-
tration does not induce signs of distress in mice. It was 
surprising to observe, using in vivo optical imaging, that 
mice receiving Cy5.5-AuNPs showed retention of parti-
cles in the brain for more than 20 days. Furthermore, in 
this experimental setting we observed that the fluores-
cence emitted by both Cy5.5 and Au in brain sections 
were perfectly overlapped, suggesting a high stability of 
the Cy5.5 tag grafted on Au surfaces. These results sug-
gest that functionalized AuNPs entering the CNS escape 
the degradation and are more stable in the CNS than 
in other organs, such as the liver [45]. The diffusion of 
Cy5.5-AuNPs in the CNS parenchyma was surprisingly 
wide, and some neurons positive for them localized sev-
eral hundreds of microns away from the ventricular cav-
ity. The mechanism of diffusion of such particles is still 
unknown, but we could speculate that these such small 
particles can passively diffuse in the extracellular matrix 
before being up taken by endocytosis. However, dou-
ble staining of Cy5.5-AuNPs and markers of neurons, 
microglia and astrocytes, revealed that AuNPs uptake 
was prominent in neurons, while only few microglia 
efficiently incorporate such particles. The high stability 
of Cy5.5-AuNPs in the brain can be due to their rapid 
uptake by cells, that prevents their removal by convec-
tive lymphatic fluxes of the CSF [46]. In addition, PEG 
functionalization is helping to prevent their uptake by 
peri-vascular macrophage, thus increasing the half-life 
of Cy5.5-AuNPs. Thus, our study clarifies the routes and 
the mechanisms of functionalized AuNPs distribution, 
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kinetic and stability after entering the brain. We observed 
a relevant AuNPs uptake in neurons and microglia far 
from the CM. We also observed their uptake in intra-
cellular compartments (mainly lysosomes), suggest-
ing a movement of Cy5.5-AuNPs through membrane 
compartments.
Conclusion
We have demonstrated that Cy5.5-AuNPs are highly 
stable upon their entry into the CNS, probably due 
to their resistance to cellular metabolism. We have 
shown that AuNPs are efficiently taken up by neurons 
and concentrate into intracellular compartments. In 
principle, their long stability and their ability to target 
intracellular vesicles in neurons could be exploited in 
disorders showing disrupted lysosomal homeostasis in 
neurons, such as the wide family of Lysosomal Stor-
age Diseases [47]. AuNPs could be also exploited in 
brain cancer radiotherapy, because PEG-coated AuNPs 
can accumulate in brain tumors and can be efficiently 
used for increasing radiotherapy efficiency [8]. Thus, 
our experimental evidence showing a long-lasting 
PEG-AuNPs accumulation in neurons upon intrathe-
cal injection suggests that this route of administration 
could be potentially used for radiotherapy enhancing 
agents in CNS tumors as well as in Lysosomal Storage 
Diseases.
Methods
Synthesis of PEG‑functionalized AuNPs
Synthesis of PEG-functionalized AuNPs was per-
formed following our published methods [32]. Cyanine 
5.5 (Cy5.5) NHS ester was purchased from Lumi-
probe (Hunt Valley, Maryland 21030, USA) and stored 
in the dark at − 20  °C. All glassware used for AuNP 
synthesis was cleaned with aqua regia (HCl(37%)/
HNO3(65%) 3/1). A water mixture of sodium citrate 
(9 ml, 2%),  HAuCl4·3H2O (7.0 ml, 10 mM) and  AgNO3 
(420  μl, 0.1%) was stirred at room temperature for 
6 min and added to 250 ml of boiling water. The mix-
ture was stirred (750  rpm) for 1  h at 100  °C, then the 
Fig. 6 Distribution of Cy5.5-AuNPs+NeuN+ in ICM-injected mice. A, B FLI scans in a control mouse (Cy5.5) and in a mouse receiving Cy5.5-AuNPs 
both sacrificed 15 days after the injection. The Epifluorescence scale is plotted on the right side of A. Representative confocal scans for NeuN, Cy5.5 
and Au in the pons/medulla of these mince are shown in C, D (n = 3 for each group). D Is a confocal image obtained stitching six independent 
pictures. Percentages of  NeuN+Cy5.5+Au+ were established in mice receiving Cy5.5-AuNPs scoring cells in the superimposed ROI (200 × 500 µm) 
and data are plotted in E. Arrows of D show  NeuN+Cy5.5+Au+ cells. F A confocal cross section of a  NeuN+ cells expressing Au and Cy5.5. Scale bar 
100 µm for C, D and 10 µm for F 
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seed solution was allowed to cool to room tempera-
ture. Glycerol (5  ml) was added and the suspension 
was stirred for 15 min. A second aliquot of sodium cit-
rate (10 ml, 1%),  HAuCl4 (7.5 ml, 10 mM) and  AgNO3 
(426 μl, 0.1%) was separately stirred for 6 min and then 
added to the colloidal solution, followed immediately 
by a solution of hydroquinone (8  ml, 1%). The result-
ing solution was allowed to age, stirring at 750  rpm 
for 1  h at room temperature. The reddish solution of 
citrate-capped AuNPs was directly used without puri-
fication to functionalize the gold surface. A mixture 
of  CH3O-PEG5000-SH/NH2-PEG5000-SH 9/1 (30  mg, 
Rapp Polymer GmbH) was dissolved in 5  ml of water 
and NaOH (8  mg) and added to the mixture contain-
ing AuNPs while argon was bubbled in the solution 
(for 5  min). The reaction mixture was stirred for 48  h 
at room temperature. PEG-AuNPs were then concen-
trated and purified by mean of Amicon centrifugal Fil-
ter units to a final volume of 11 ml.
Synthesis of Cy5.5‑AuNPs
Five ml of PEG-functionalized AuNPs (10% PEG-NH2), in 
milliQ water, were filtered by centrifugal filtration (10,000 
MWCO, Vivaspin filters) to remove the solvent, and were 
re-suspended in borate buffer at pH 8. To this solution, 
Cy5.5-NHS ester (450  µg, 0.00063  mmol, Lumiprobe-
Hunt Valley, Maryland 21030, USA) dissolved in DMSO 
(500 µl) was added at room temperature. We adjusted pH 
to 8.5 by adding NaOH 0.2 N, and the reaction mixture 
was stirred at room temperature in the dark for ca. 18 h. 
Then, the solvent was removed by centrifugal filtration 
(10,000 MWCO, Vivaspin filters) and Cy5.5-AuNPs were 
washed with tBuOH/H2O 1:1 until the collected wash-
ing solution was colorless (the absence of Cy5.5 adsorp-
tion was checked through UV–Vis spectroscopy). Finally, 
Cy5.5-AuNPs were washed with milliQ water to remove 
tBuOH traces, were dissolved in 5  ml milliQ water and 
stored at 4 °C.
Characterization of Cy5.5‑AuNPs
Dynamic light scattering (DLS) was employed to meas-
ure hydrodynamic diameter and Zeta-potential, deter-
mined by using a 90 Plus Particle Size Analyzer from 
Brookhaven Instrument Corporation (Holtsville, NY) 
operating at 15  mW of a solid-state laser (λ = 661  nm), 
using a scattering angle of 90°, equipped with an AQ-809 
electrode, operating at applied voltage of 120  V. DLS 
samples were prepared by filtration with a 0.45 μm cellu-
lose acetate syringe filter before loading into the cuvette, 
in order to remove large interfering particulate matter. 
Each sample was allowed to equilibrate for 3  min prior 
to start the measurement. Three to ten independent 
measurements of 60 s duration were performed, at 25 °C. 
The hydrodynamic diameter calculation was performed 
using Mie theory. The absolute viscosity and refrac-
tive index values of the medium were respectively set to 
0.911 cP and 1.334. The Zeta-potential was automatically 
calculated from electrophoretic mobility based on the 
Smoluchowski theory. A viscosity of 0.891 cP, a dielectric 
constant of 78.6, and a Henry function of 1.5 were used 
for the calculations. UV/Vis spectra were recorded on an 
Agilent 8453 instrument by using a disposable cuvette 
with 1  cm optical path length for the measurements. 
Transmission electron microscopy micrographs have 
been collected using a TEM-Zeiss LIBRA 200FE instru-
ment, equipped with: 200  kV FEG, in column second-
generation omega filter for energy selective spectroscopy 
(EELS) and imaging (ESI), HAADF STEM facility, EDS 
probe for chemical analysis, integrated tomographic 
HW and SW systems. TEM specimens were prepared by 
dropping an aqueous solution of AuNPs onto a carbon-
coated copper grid (300 mesh) and evaporating the sol-
vent. The particle size distribution was estimated by using 
ITEM-TEM Imaging platform—Olympus Soft Imaging 
Solutions. The number of measured nanoparticles for 
each sample resulted to be around 250. Au concentra-
tion was determined via Inductively Coupled Plasma-
Optical Emission Spectrometers (ICP-OES; iCAP 6300 
Duo, Thermofisher). Samples (1  ml each) were digested 
in a glass vial over a heating plate with aqua regia (2 ml), 
repeating the treatment for four times. The explant sam-
ples were digested over a heating plate with a solution 
of  HNO3/H2O2 30% m/m (3/1, 2 ml) for two times, fol-
lowed by aqua regia (2 ml) for three times. The dry resi-
dues were dissolved in a 0.5 M HCl aqueous solution and 
diluted. The limit of detection (lod) calculated for gold 
was 0.01 ppm.
Nanoparticle administration in vivo
Mice were maintained under pathogen-free conditions 
at San Raffaele Hospital mouse facility (Milan, Italy). All 
efforts were made to minimize animal suffering and to 
reduce the number of mice used in accordance with the 
European Communities Council Directive of 24 Novem-
ber 1986 (86/609/EEC). Five weeks CD1 (Charles Rivers) 
females were given an injection of anesthetic (2,2,2-tri-
bromoethanol, 10  mg/ml; 1/27 of body weight), then 
10 µl of Cy 5.5-AuNPs (0.11 µg/µl) were injected within 
the cisterna magna of mice using a 27-gauge stainless 
steel needle curved (40°) at 3.5 mm from the tip, so that 
it was J-shaped [48]. IV delivery was obtained injecting 
mice in the tail vein with 200 µl of Cy5.5-AuNPs (0.11 µg/
µl). Intra parenchymal injection was obtained by deliver-
ing 1 μl of Cy 5.5-AuNPs (1.1 µg/µl) in the brain by a sin-
gle stereotaxic injection at the following coordinates: A 
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− 0.5, 0; L, + 1.2; and D, − 0.8 [49]. Control mice received 
injections of soluble Cy5.5 or vehicle (sterile saline). To 
calculate the appropriate amount of Cy5.5 to be deliv-
ered into the cisterna magna, we compared curves of 
fluorescence from serial dilutions (dilution factor = 10) 
of Cy5.5 and Cy5.5-AuNPs, using the IVIS SpectrumCT 
System. Control mice received Cy5.5 at the concentra-
tion that produced the same fluorescence level of the 
Cy5.5-AuNPs used in our experiments. At the sacrifice 
(2, 5, 15 and 30 days after the delivery of particles), mice 
were given an overdose of anesthetic drugs and were 
transcardially perfused with saline followed by 80/100 ml 
4% paraformaldehyde in PBS 1×, pH 7.2 (Sigma). Brains 
were post fixed in the same solution for 12 h at + 4  °C. 
Tissues were cryoprotected in PBS/30% Sucrose (Sigma), 
embedded in OCT inclusion media and stored at − 80 °C 
before processing. The metal content in brain explants 
was determined by ICP-OES. Mice were perfused with 
sterile saline and brains homogenized in PBS solutions. 
Sample were digested in a glass vial over a heating plate 
with aqua regia according our published methods [32]. 
The dry residuals were dissolved in a HCl aqueous solu-
tion 0.5 M and properly diluted.
In vivo imaging
Mice images were acquired by placing the animals at 
37  °C under gaseous anesthesia (2–3% isoflurane and 
1 l/min oxygen). FLI was performed by IVIS Spectrum-
CT System (Perkin Elmer), equipped with a low noise, 
back-thinned, back-illuminated CCD camera cooled 
at − 90  °C and a with quantum efficiency in the visible 
range > 85%. Images were obtained using the following 
settings: exposure time = auto, binning = 8, f = 2 and 
a field of view equal to 13  cm (field C); when needed 
spectral unmixing, FLI was obtained using the following 
excitation/emission filters: 640/680, 640/700, 640/720, 
640/740, 675/720, 675/740, 675/760  nm. Acquisitions 
were done before and after the injection of particles 
with the following time sampling: 1 h, and 1, 2, 3, 4, 7, 
10, 16, 25 days after the delivery of Cy5.5-AuNPs. Anal-
yses were done in a region of interest (ROI) overlapping 
the brain, measuring the radiant efficiency within this 
ROI using images acquired with the 675/720 filters. The 
FR(ti) was calculated on ROI sampled at different time 
points  (ti) and normalized on images acquired before 
injection or particles  (t0) to quantify the magnitude of 
the fluorescence signal: FR(ti) = [ROI(ti))/(ROI(t0)]. 
Spectral un-mixing of the FLI data was performed on 
selected images in order to show the specificity of the 
fluorescence signal over the tissue auto-fluorescence. 
All the images were acquired and analyzed using Living 
Image 4.5 (Perkin Elmer).
Immunofluorescence and electron microscopy
Immunofluorescence and electron microscopy have been 
done according the following methods [49–51]. Brains 
were sagittal or coronal sectioned (20 µm) and one sec-
tion every 250  µm was used for immunofluorescence. 
Slides were washed in PBS 1× and incubated with the fol-
lowing blocking buffer: PBS 1×, BSA 1 mg/ml, FBS 10%, 
Triton 0.1% (Sigma). Primary antibodies were diluted 
in the same buffer and incubated on section for 12 h at 
+ 4  °C. Secondary antibodies (Alexa-flour conjugated) 
were incubated according to manufacturer’ instructions, 
then sections were cover slipped with Dako mounting 
mix. The following antibodies were used: mouse α-NeuN 
(Millipore, 1:800); rabbit α-MBP (Millipore) 1: 500; rabbit 
α-Iba1 (Wako) 1:400; rabbit α-GFAP (Dako) 1:1000. Sec-
ondary, Alexafluor 488-conjugated antibodies were used 
according to manufactures’ instructions. Acquisitions 
were performed with a Leica SP8 confocal microscopy 
equipped with a 40× objective and with super-sensitive 
HyD detectors. Fluorescence was recorded as square 
8-bit images (1024 × 1024 pixels) and stored as separate 
image stacks for each channel. Alignment of images to 
obtain largest field of view of coronal sections was done 
by automatic stitching of stack images using the Leica 
(Las-X, Leica). Acquisition of fluorescence from Au was 
done according published methods [38]. We used an exci-
tation wavelength of 532 nm, while signals were acquired 
in the 594–640  nm window. Images showed the maxi-
mal projections of Z-stacks acquired with a 0.8 µm step 
or cross sections of selected cells acquired with 0.3  µm 
step. Images were pseudo-colored using Las-X software. 
For EM analysis, brains were post-fixed in 0.12 M phos-
phate buffer supplemented with 2% glutaraldehyde, and 
further sectioned to get a region encompassing the 4th 
ventricle and the cerebellum. These parts were further 
post-fixed with osmium tetroxide and embedded in Epon 
(Fluka, Buchs, Switzerland). Ultrathin sectioning of the 
CNS allowed the generation of 70 nm sections that were 
imaged by a transmission electron microscope (LEO 
912AB). In vitro quantification of Cy5.5-AuNPs fluores-
cence were performed using the FLI (FLI) acquired with 
IVIS SpectrumCT System scanner (Perkin Elmer).
Primary hippocampal cultures and sytox determination
Neurons were obtained from the hippocampus of CD1 
(Charles Rivers) mice at the embryonic stage of E17.5. 
Hippocampi were mechanically dissociated in cold HBSS 
supplemented with 0.6% glucose, 5  mM HEPES (pH 
7.4) (Sigma Aldrich). Cells were suspended in culture 
medium containing Neurobasal Medium (Thermo Fisher 
Scientific) supplemented with: N2 (Thermo Fisher Scien-
tific), B27 (GIBCO), 5 mM HEPES (pH 7.4), 0.6% glucose 
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(Sigma Aldrich) and 0.5% glutamine (Thermo Fisher Sci-
entific) in the absence of antimitotic and antibiotic drugs. 
Fifteen days after plating neurons were incubated with 
increasing amounts of Cy 5.5-AuNPs (1, 0.1, 0.01 and 
0.001  mg/ml) for 24  h. Percentages of dying cells were 
estimated labelling cells with Sytox and Hoechst (Molec-
ular Probes). Automated imaging was performed using 
the  ArrayScan® (ThermoFisher) equipped with a 40× air 
objective. More than 300 fields per conditions have been 
assayed for the statistical evaluation of cell death.
Statistics
Data are expressed with the mean ± standard error 
(± S.D.). Normality of dataset was assessed in each 
experiment by applying either Kolmogorov–Smirnov test 
(with Dallas–Wilkinson–Lille for P value) or Skewness 
test. Comparisons were done using: unpaired t-test, one-
way analysis of variance (ANOVA), followed by Tukey 
post hoc test. Statistical tests were carried out using 
PRISM5.01 (GraphPad Software).
Additional files
Additional file 1: Figure S1. Synthetic route for Cy5.5-AuNPs. General 
scheme for the synthesis of surface-engineered Cy5.5-AuNPs. PEG-AuNPs 
are synthesized using sodium citrate as reducing agent and preliminary 
capping ligand. Purified PEG-AuNPs have been functionalized by forming 
a stable amide bond between PEG-NH2 and NHS activated chromophore 
Cy5.5.
Additional file 2: Figure S2. Cy5.5-AuNPs in tail vein-injected mice. 
Panels A shows the FLI analysis of mice receiving a single injection of 
Cy5.5-AuNps in the tail vein that were sacrificed 5 days after the injection. 
Epifluorescence scale is plotted on the left side of the panel A. A repre-
sentative confocal scan of the cerebral cortex showing NeuN and Cy5.5 
in mice injected with the vehicle and in mice injected with Cy5.5-AuNPs 
are shown in panels B and C, respectively (n = 3 for each group). Scale bar 
100 µm.
Additional file 3: Figure S3. Cy5.5-AuNPs in intra parenchymal injected 
mice. Panel A shows FLI analysis in brains receiving a single intra paren-
chymal injection of Cy5.5-AuNPs. Epi-fluorescence scale is plotted on the 
right side of the panel. Arrow in panel A indicates one of these brains that 
was subsequently sectioned in coronal slabs and further assayed for FLI 
FLI analysis (B). Epi fluorescence scale is plotted on the right side of the 
panel. Panels C and D show confocal scans of the cerebral cortex from a 
Cy5.5-AuNPs-injected mouse labelled for Iba1, Cy5.5 and Au.  Iba1+ cells 
were scored in both the contralateral (C) and the ipsilateral cerebral cortex 
(D). Percentages (± S.D.) of  Iba1+ cells are shown in the histogram of 
panel E (n = 3). Arrow in panel D indicates a single  Iba1+ cell that is shown 
at high magnification in the confocal cross section of panel F. Scale bar 
100 µm. * p < 0.05 unpaired t test.
Additional file 4: Figure S4. Co-localization of Au, Cy5.5 and NeuN in 
cortical neurons. Coronal sections from mice receiving a single intra-
parenchymal injection of Cy5.5-AuNPs were labelled for NeuN (C) and 
submitted to confocal imaging for Au (A) and Cy5.5 (B). To maximize the 
probability to find triple positive cells we did the imaging in the cortical 
wall in a region that was adjacent the site of injection. Merge panel in 
D show co-localization of Cy5.5 and Au in  NeuN+ cells (n = 3). Scale bar 
30 µm.
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